CagriSema (Cagrilintide 2.5 mg + Semaglutide 2.5 mg)

CagriSema is a combination research system incorporating Cagrilintide and Semaglutide. This formulation contains Cagrilintide 2.5 mg + Semaglutide 2.5 mg.

Cagrilintide is a long-acting amylin analogue investigated in research involving amylin receptor-related signaling, appetite and satiety regulation, food intake, and energy-balance mechanisms.

Semaglutide is a GLP-1 receptor agonist studied in connection with GLP-1 receptor signaling, glucose homeostasis, insulin and glucagon regulation, gastric emptying, and energy intake.

As a combined research formulation, CagriSema provides a system for investigating interactions between amylin and GLP-1 signaling pathways and their relationships with appetite regulation, energy homeostasis, glucose metabolism, and body-weight-related metabolic mechanisms.

The safety, efficacy, or appropriate human dosing of this specific 2.5 mg + 2.5 mg formulation should not be inferred from research or approved uses involving the individual components.

Livraison standard offerte dès 50 $ vers les États-Unis, le Canada, le Mexique et l'Europe. Expédition sous 1 jour ouvré.

Pas convaincu ? Renvoyez le produit sous 30 jours pour un remboursement intégral, même ouvert.